Skip Navigation
JavaScript is disabled in your browser, you must have JavaScript enabled to view this content.
Search:
JavaScript is disabled in your browser, you must have JavaScript enabled to view this content.
Vaccines Search
Preventive HIV Vaccine Trials (For HIV-negative individuals)
New and Recruiting Trials
Closed Trials
Therapeutic AIDS Vaccine Trials (For HIV-positive individuals)
New and Recruiting Trials
Closed Trials
Home
>
Vaccines
>
Search Vaccines
Text Size
Print
RSS
Order Pubs
20 studies were found.
Include trials that are no longer recruiting patients
Completed
Safety of an HIV DNA Vaccine Given to HIV Uninfected Adults
Condition: HIV Infections
En español
Completed
Safety and Effectiveness of the Vaccine ALVAC-HIV vCP205 in HIV-Negative Adult Volunteers in Uganda
Condition: HIV Infections
En español
Completed
Safety and Immune Response Study of the Vaccine ALVAC vCP1452 Alone or in Combination With AIDSVAX B/B
Condition: HIV Infections
En español
Completed
A Phase I Study of the Safety and Immunogenicity of rgp120/HIV-1IIIB Vaccine in Healthy Adult Subjects (NOTE: Study Extended ONLY for Subjects Who Have Previously Received rgp120/HIV-1IIIB or rgp120/HIV-1MN on VEU 006 or VEU 006 Rollover Study)
Condition: HIV Infections
Completed
A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive Individuals
Condition: HIV Infections
Completed
A Phase I Multicenter Study of the Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine Given Either Alone or in Combination With IIIB rgp120/HIV-1 Vaccine in Healthy Adult Subjects (NOTE: Original Study Extended ONLY for Patients Previously Enrolled on VEU 009)
Condition: HIV Infections
Terminated
Safety and Effectiveness of Two Different Formulations of an HIV Vaccine in Infants Born to HIV-Infected Women
Condition: HIV Infections; HIV Seronegativity
Completed
Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults
Condition: HIV Infections
Completed
Safety of and Immune Response to an HIV Vaccine (SF-2 gp120) With or Without MTP-PE/MF59 Adjuvant
Condition: HIV Infections
Completed
A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox-gp160 MN (ALVAC vCP125, HIV-1 gp160 MN) in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Completed
Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)
Condition: HIV Infections
Completed
A Study of the Effectiveness of an HIV Vaccine (ALVAC vCP205) to Boost Immune Functions in HIV-Negative Volunteers Who Have Already Received an HIV Vaccine
Condition: HIV Infections; HIV Seronegativity
Completed
Safety and Immunogenicity Study of Recombinant Modified Vaccinia Virus Ankara (MVA) Virus to Treat HIV Infection
Condition: HIV Infections
Completed
HIV-1 Vaccine Test in Uninfected Adult Volunteers
Condition: Healthy
Completed
A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules
Condition: HIV Infections
Completed
A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers
Condition: HIV Infections
Completed
A Phase II Clinical Trial to Evaluate the Immunogenicity and Reactogenicity of the Recombinant HIV-1 Envelope Vaccines SF-2 rgp120 (CHO) [Chiron Vaccines] in MF59 Adjuvant and MN rgp120/HIV-1 [VaxGen] in Alum Adjuvant in Healthy Adults
Condition: HIV Infections
Completed
A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)
Condition: HIV Infections
Completed
A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 100 Mcg of Env 2-3 in MF59
Condition: HIV Infections; HIV Seronegativity
Completed
Candidate HIV Vaccine
Condition: HIV Infections